Abstract
The rapid emergence of SARS-CoV-2 mutants with new phenotypic properties is a critical challenge to the control of the ongoing pandemic. B.1.1.7 was monitored in the UK through routine testing and S-gene target failures (SGTF), comprising over 90% of cases by March 2021. Now, the reverse is occurring: SGTF cases are being replaced by an S-gene positive variant, which we associate with B.1.617.2. Evidence from the characteristics of S-gene positive cases demonstrates that, following importation, B.1.617.2 is transmitted locally, growing at a rate higher than B.1.1.7 and a doubling time between 5-14 days. S-gene positive cases should be prioritised for sequencing and aggressive control in any countries in which this variant is newly detected.
One-Sentence Summary The B.1.617.2 variant of SARS-CoV-2 is replacing B.1.1.7 and emerging as the dominant variant in England, evidenced by sustained local transmission.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
UKRI through the JUNIPER consortium (grant number MR/V038613/1), LDa LDy, JRG, MJK, CO, LG, FS, LP, DJP MRC (grant number MC/PC/19067), LDa, RC, EBP, MJK MRC (grant number MR/V009761/1) EMH, MJT, LDy, MJK MRC (unit programme number MC UU 00002/11), DJP EPSRC (EP/V051555/1), LDa, DW EPSRC through the The Alan Turing Institute, grant EP/N510129/1), LDa, DW National Institute of Health Research UK: EBP, Pfizer through investigator-led grants on respiratory tract infections. LDa Wellcome Trust and the Royal Society (grant 202562/Z/16/Z), LP, HS and CO Alexander von Humboldt Foundation, HS
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data were supplied under strict data protection protocols agreed between the researchers and Public Health England. The ethics of the use of these data for these purposes was agreed by Public Health England with the Governments SPI-M(O) / SAGE committees. The research was assessed as not needing NHS Research Ethics Committee review.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available to researchers with data sharing agreements in place with Public Health England.
